You are here

Our People

We work with leading research scientists to identify and nurture research that has strong clinical and commercial potential. Projects with translational potential are guided through the process by one of our experienced Business Development Managers. We build strong personal relationships with our partners and keep lines of communication open and simple to ensure the free flow of information and ideas. This ensures all potential opportunities are capitalised on as innovatively and efficiently as possible.

CRT BOARD Open

Peter Chambré, Chairman Mr. Peter A. Chambre is Chairman of CRT since October 2011. He is Independent Non-Executive Director of BTG Plc., since September 2006 and Chairman of Xellia Pharmaceuticals AS, OneMed AB and 7TM Pharma A/S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company. Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc.


 

Dr Andy Richards CBE Dr Andy Richards CBE is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Ixicio plc, Congenica Limited, Novacta Biosystems Limited, Abcodia Limited and Cambridge Temperature Concepts Limited, as well as a director of Arecor Limited, Ieso Health Limited (formerly PsychologyOnline.co.uk Limited) and Babraham Bioscience Technologies Limited. Andy is also a director of Cambridge University Health Trust and an adviser to Vectura Group plc. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT is August 2003. He is a graduate of Cambridge University with a PhD in Chemistry.


Iain Foulkes, PhD Iain was appointed as Cancer Research UK's Executive Director, Strategy and Research Funding in August 2009. Iain is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute. He then became a science writer and medical journalist, before moving into Policy and Communications at the Imperial Cancer Research Fund (ICRF). During his time at ICRF, he worked closely with Sir Paul Nurse, who at that time was Chief Executive, helping to drive through the merger of ICRF and Cancer Research Campaign to become Cancer Research UK. From January 2003, he was Director of Strategic Development in Fundraising and Supporter Marketing, and has supported the early-stage development of UK Centre for Medical Research and Innovation working with Sir Paul Nurse.


Sir Harpal S Kumar Harpal is Chief Executive of Cancer Research UK, appointed in 2007 following three years as Chief Operating Officer and five years as Chief Executive of Cancer Research Technology Limited, a wholly-owned subsidiary of Cancer Research UK. Harpal was Chair of the Taskforce and author of “Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020”, published in summer 2015. He is a Trustee of The Francis Crick Institute in London. He also chairs the National Cancer Advisory Group is a member of the MedCity Advisory Board. He is a Director of UICC. He was knighted in the 2016 New Years Honours list.


 

Deborah Harland Deborah has extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25 year tenure in the pharmaceutical industry. She joined SR One, the corporate venture capital arm of GlaxoSmithKline, in 2005 to establish the firm’s European investment office. Deborah is currently a member of the Board of Directors of Asceneuron, Mission Therapeutics, Bicycle Therapeutics, f-star, Atopix Therapeutics and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

CSO and CRUK-TDL Open

Clive Stanway, Chief Scientific Officer. Clive is responsible for the external scientific profile of Commercial Partnerships including development of new alliances and oversight of its key accounts. Before moving to this role, he led the drug discovery and biotherapeutic discovery activity now known as the CRUK Therapeutic Discovery Laboratories. Before CRUK was formed in 2002, he was Director of Project Development for Imperial Cancer Research Technology, a role which focused on the identification and development of projects with therapeutic potential. From his time in the private sector, he has 5 years' experience in drug discovery gained whilst working for Xenova and Prolifix where he held the positions of Head of Assay Development and Head of Biology, respectively.  In the academic part of Clive's career he held several postdoctoral positions at Oxford University rising to a junior faculty position. He has a PhD from Imperial College and a BSc from Nottingham University.


Hamish Ryder, Director of Therapeutic Discovery Laboratories. Hamish has directed drug discovery at CRUK-TDL, and it's predecessor CRT-DL, since 2008. He has led the successful transition of it's translational strategy to a themed multi-project alliance model where industry partners are involved from the earliest stages of target selection and triage. Prior to joining CRT-DL he held positions in pharmaceutical and biotech companies for over 20 years, the most recent of which was as Director of Research at Almirall, Spain’s largest pharmaceutical company. Hamish has worked in a number of therapeutic areas, including autoimmune, inflammatory, respiratory, GI, CNS and cancer. He has led organisations that have discovered multiple candidate drugs for regulatory development, thus far resulting in approved therapies for chronic obstructive pulmonary disease (Bretaris and Duaklir). Hamish obtained his first degree in Natural Sciences and a PhD in organic chemistry from the University of Cambridge.


Tim Hammonds, Deputy Director of Therapeutic Discovery Laboratories. Tim has been in his current role since April 2014. He leads multiple aspects of translational drug discovery and has strategic responsibility for the Cancer Biology Advisory Board and the design, planning, negotiation and management of multi-site academia-industry alliances. Tim joined CRUK-TDL (then CRT-DL) after 5 years postdoctoral enzymology research at the University of Leicester and had been been central to establishing their small molecule drug discovery capabilities. He has a degree in Pharmacy and a PhD in pharmaceutical chemistry and microbiology from the University of Nottingham.


> Read more about CRUK-TDL

BUSINESS DEVELOPMENT Open

 

Dr Phil Masterson, Associate Director.  Phil has been working as Associate Director of the Commercial Partnerships team since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


Dr Laura Fletcher, Associate Director. Laura obtained her first degree in Biochemistry from the University at Bristol and, after a one year sabbatical at the University of Pennsylvania, returned to Bristol to take up her PhD in insulin signalling and resistance. Her focus during this time was on cell biology and time-lapse confocal microspcopy. Shortly after completing her PhD in 2001, Laura was the co-founder of a small molecule drug discovery company called ProXara, where she spent the following five years developing fluorescent cellular screens focussed on identifying inhibitors of protein localisation events for various cancer targets. During this time she also managed the associated patent portfolio and was involved in seed fund raising and business plan development. Laura joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team, in summer 2006, and in June 2011 was promoted to Associate Director. 


 Dr Angus Lauder, Associate Director. After obtaining a BSc in Molecular Biology from the University of Edinburgh, Angus moved to London to complete a PhD at the Institute of Cancer Research working on signal transduction and gene expression of the oncogene c-Myb. He then undertook post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge working on models of leukaemia and the roles of cytokines in controlling leukaemia development. Angus has worked for CRUK's Commercial Partnerships team (joining when it was Cancer Research Technology) for twelve years during which time he has worked on a wide range of therapeutic projects, research technologies and biomarker opportunities. During this time he has gained in-depth experience of a broad set of translational and commercialisation models including licensing, industry-academia alliances and formation of a number of spin-out companies. Angus currently manages a team of five business managers and provides strategic input and advice to the team to facilitate translation of technologies from a range of university partners using many different commercialisation routes and models.


Dr Phil Elstob, Head of Commercial Portfolio. Phil leads a team with responsibility for CRUK's portfolio of over 100 licences and ~30 equity holdings. Phil joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team, following the completion of a PhD in developmental biology at the MRC’s National Institute for Medical Research (Mill Hill, London) and has since gained over 15 years’ experience in the development, IP management and commercialisation of cancer therapeutics. In 2006 Phil moved back to his native northeast to set up a strategic partnership with Newcastle University, and he currently works part-time for both CRUK and the University. More recently Phil spent two and a half years as part-time Chief Executive Officer of Demuris Limited, a University spin out company focused on antibiotic drug discovery. Phil is also a member of the PraxisUnico Training Committee, responsible for the design and delivery of training courses for knowledge exchange and commercialisation professionals.


> Read more about our services

US OFFICE Open

 Andrea Schievella, President of our US Office. Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since joining the organisation she has been building relationships between CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to this role, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  

 


> View our projects

CLINICAL DEVELOPMENT PARTNERSHIPS Open

Dr Victoria John, Head of Clinical Partnerships. Vicky joined Cancer Research UK in March 2008. In her role as Head of Clinical Partnerships, Vicky is responsible for sourcing new projects for the CRUK Centre for Drug Development and negotiating clinical trial agreements for CDP projects. Prior to joining Cancer Research UK, Vicky worked at Cancer Research Technology for 9 years including 4 years as a Senior Business Manager and 2 years as Head of Licensing for the CDP initiative. During her time at Cancer Research Technology Vicky concluded a number of major collaboration and licence agreements, and spent 2 years as a non-executive Board Director for Hybrid Systems. Vicky holds a first class BSc (Hons) in Molecular Biology from the University of Manchester and, following a period of working in assay development at Glaxo-Wellcome, completed a PhD in Oncology from the Paterson Institute for Cancer Research.


> Read more about CDP

RESEARCH TOOLS Open

Dr Melanie Hardman, Head of Ximbio Melanie has 17 years experience in commercial life science business development within the scientific software and life science reagents sectors. Prior to this role Melanie worked for Oxford Molecular, Accelrys and LION Bioscience primarily in customer facing sales and pre-sales roles with global pharma, biotech and academic customers. Melanie has been with Ximbio for over 10 years and heads up the research reagents business unit, which in this time has doubled in size (2000+ research reagents) and revenues and launched an online portal, Ximbio (www.ximbio.com). The business has a dedicated team and is responsible for commercialising non patented materials generated from CRUK funded research and making these valuable tools widely and easily available through sales and licensing to the life science reagents industry. Melanie has a PhD in microbiology.


> Read more about research tools

  • Peter Chambré, Chairman Mr. Peter A. Chambre is Chairman of CRT since October 2011. He is Independent Non-Executive Director of BTG Plc., since September 2006 and Chairman of Xellia Pharmaceuticals AS, OneMed AB and 7TM Pharma A/S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company. Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc.


     

    Dr Andy Richards CBE Dr Andy Richards CBE is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Ixicio plc, Congenica Limited, Novacta Biosystems Limited, Abcodia Limited and Cambridge Temperature Concepts Limited, as well as a director of Arecor Limited, Ieso Health Limited (formerly PsychologyOnline.co.uk Limited) and Babraham Bioscience Technologies Limited. Andy is also a director of Cambridge University Health Trust and an adviser to Vectura Group plc. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT is August 2003. He is a graduate of Cambridge University with a PhD in Chemistry.


    Iain Foulkes, PhD Iain was appointed as Cancer Research UK's Executive Director, Strategy and Research Funding in August 2009. Iain is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute. He then became a science writer and medical journalist, before moving into Policy and Communications at the Imperial Cancer Research Fund (ICRF). During his time at ICRF, he worked closely with Sir Paul Nurse, who at that time was Chief Executive, helping to drive through the merger of ICRF and Cancer Research Campaign to become Cancer Research UK. From January 2003, he was Director of Strategic Development in Fundraising and Supporter Marketing, and has supported the early-stage development of UK Centre for Medical Research and Innovation working with Sir Paul Nurse.


    Sir Harpal S Kumar Harpal is Chief Executive of Cancer Research UK, appointed in 2007 following three years as Chief Operating Officer and five years as Chief Executive of Cancer Research Technology Limited, a wholly-owned subsidiary of Cancer Research UK. Harpal was Chair of the Taskforce and author of “Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020”, published in summer 2015. He is a Trustee of The Francis Crick Institute in London. He also chairs the National Cancer Advisory Group is a member of the MedCity Advisory Board. He is a Director of UICC. He was knighted in the 2016 New Years Honours list.


     

    Deborah Harland Deborah has extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25 year tenure in the pharmaceutical industry. She joined SR One, the corporate venture capital arm of GlaxoSmithKline, in 2005 to establish the firm’s European investment office. Deborah is currently a member of the Board of Directors of Asceneuron, Mission Therapeutics, Bicycle Therapeutics, f-star, Atopix Therapeutics and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

  • Clive Stanway, Chief Scientific Officer. Clive is responsible for the external scientific profile of Commercial Partnerships including development of new alliances and oversight of its key accounts. Before moving to this role, he led the drug discovery and biotherapeutic discovery activity now known as the CRUK Therapeutic Discovery Laboratories. Before CRUK was formed in 2002, he was Director of Project Development for Imperial Cancer Research Technology, a role which focused on the identification and development of projects with therapeutic potential. From his time in the private sector, he has 5 years' experience in drug discovery gained whilst working for Xenova and Prolifix where he held the positions of Head of Assay Development and Head of Biology, respectively.  In the academic part of Clive's career he held several postdoctoral positions at Oxford University rising to a junior faculty position. He has a PhD from Imperial College and a BSc from Nottingham University.


    Hamish Ryder, Director of Therapeutic Discovery Laboratories. Hamish has directed drug discovery at CRUK-TDL, and it's predecessor CRT-DL, since 2008. He has led the successful transition of it's translational strategy to a themed multi-project alliance model where industry partners are involved from the earliest stages of target selection and triage. Prior to joining CRT-DL he held positions in pharmaceutical and biotech companies for over 20 years, the most recent of which was as Director of Research at Almirall, Spain’s largest pharmaceutical company. Hamish has worked in a number of therapeutic areas, including autoimmune, inflammatory, respiratory, GI, CNS and cancer. He has led organisations that have discovered multiple candidate drugs for regulatory development, thus far resulting in approved therapies for chronic obstructive pulmonary disease (Bretaris and Duaklir). Hamish obtained his first degree in Natural Sciences and a PhD in organic chemistry from the University of Cambridge.


    Tim Hammonds, Deputy Director of Therapeutic Discovery Laboratories. Tim has been in his current role since April 2014. He leads multiple aspects of translational drug discovery and has strategic responsibility for the Cancer Biology Advisory Board and the design, planning, negotiation and management of multi-site academia-industry alliances. Tim joined CRUK-TDL (then CRT-DL) after 5 years postdoctoral enzymology research at the University of Leicester and had been been central to establishing their small molecule drug discovery capabilities. He has a degree in Pharmacy and a PhD in pharmaceutical chemistry and microbiology from the University of Nottingham.


    > Read more about CRUK-TDL

  •  

    Dr Phil Masterson, Associate Director.  Phil has been working as Associate Director of the Commercial Partnerships team since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


    Dr Laura Fletcher, Associate Director. Laura obtained her first degree in Biochemistry from the University at Bristol and, after a one year sabbatical at the University of Pennsylvania, returned to Bristol to take up her PhD in insulin signalling and resistance. Her focus during this time was on cell biology and time-lapse confocal microspcopy. Shortly after completing her PhD in 2001, Laura was the co-founder of a small molecule drug discovery company called ProXara, where she spent the following five years developing fluorescent cellular screens focussed on identifying inhibitors of protein localisation events for various cancer targets. During this time she also managed the associated patent portfolio and was involved in seed fund raising and business plan development. Laura joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team, in summer 2006, and in June 2011 was promoted to Associate Director. 


     Dr Angus Lauder, Associate Director. After obtaining a BSc in Molecular Biology from the University of Edinburgh, Angus moved to London to complete a PhD at the Institute of Cancer Research working on signal transduction and gene expression of the oncogene c-Myb. He then undertook post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge working on models of leukaemia and the roles of cytokines in controlling leukaemia development. Angus has worked for CRUK's Commercial Partnerships team (joining when it was Cancer Research Technology) for twelve years during which time he has worked on a wide range of therapeutic projects, research technologies and biomarker opportunities. During this time he has gained in-depth experience of a broad set of translational and commercialisation models including licensing, industry-academia alliances and formation of a number of spin-out companies. Angus currently manages a team of five business managers and provides strategic input and advice to the team to facilitate translation of technologies from a range of university partners using many different commercialisation routes and models.


    Dr Phil Elstob, Head of Commercial Portfolio. Phil leads a team with responsibility for CRUK's portfolio of over 100 licences and ~30 equity holdings. Phil joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team, following the completion of a PhD in developmental biology at the MRC’s National Institute for Medical Research (Mill Hill, London) and has since gained over 15 years’ experience in the development, IP management and commercialisation of cancer therapeutics. In 2006 Phil moved back to his native northeast to set up a strategic partnership with Newcastle University, and he currently works part-time for both CRUK and the University. More recently Phil spent two and a half years as part-time Chief Executive Officer of Demuris Limited, a University spin out company focused on antibiotic drug discovery. Phil is also a member of the PraxisUnico Training Committee, responsible for the design and delivery of training courses for knowledge exchange and commercialisation professionals.


    > Read more about our services

  •  Andrea Schievella, President of our US Office. Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since joining the organisation she has been building relationships between CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to this role, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  

     


    > View our projects

  • Dr Victoria John, Head of Clinical Partnerships. Vicky joined Cancer Research UK in March 2008. In her role as Head of Clinical Partnerships, Vicky is responsible for sourcing new projects for the CRUK Centre for Drug Development and negotiating clinical trial agreements for CDP projects. Prior to joining Cancer Research UK, Vicky worked at Cancer Research Technology for 9 years including 4 years as a Senior Business Manager and 2 years as Head of Licensing for the CDP initiative. During her time at Cancer Research Technology Vicky concluded a number of major collaboration and licence agreements, and spent 2 years as a non-executive Board Director for Hybrid Systems. Vicky holds a first class BSc (Hons) in Molecular Biology from the University of Manchester and, following a period of working in assay development at Glaxo-Wellcome, completed a PhD in Oncology from the Paterson Institute for Cancer Research.


    > Read more about CDP

  • Dr Melanie Hardman, Head of Ximbio Melanie has 17 years experience in commercial life science business development within the scientific software and life science reagents sectors. Prior to this role Melanie worked for Oxford Molecular, Accelrys and LION Bioscience primarily in customer facing sales and pre-sales roles with global pharma, biotech and academic customers. Melanie has been with Ximbio for over 10 years and heads up the research reagents business unit, which in this time has doubled in size (2000+ research reagents) and revenues and launched an online portal, Ximbio (www.ximbio.com). The business has a dedicated team and is responsible for commercialising non patented materials generated from CRUK funded research and making these valuable tools widely and easily available through sales and licensing to the life science reagents industry. Melanie has a PhD in microbiology.


    > Read more about research tools